Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Phase II Study Assessing Potential Predictive Tumor Markers in Patients With Metastatic Colorectal Cancer and Wild Type K-RAS Tumor Treated With FOLFOX Plus Panitumumab as First-line Therapy

Next Previous
Search
Trial Profile

An Open Label, Phase II Study Assessing Potential Predictive Tumor Markers in Patients With Metastatic Colorectal Cancer and Wild Type K-RAS Tumor Treated With FOLFOX Plus Panitumumab as First-line Therapy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fluorouracil (Primary) ; Folinic acid (Primary) ; Oxaliplatin (Primary) ; Panitumumab (Primary)
  • Indications Colorectal cancer
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Acronyms PULSE

    • Most Recent Events

    • 15 Nov 2018 According to a Biocartis media release, results of an analysis of two prospective clinical trials (PULSE; NCT01288339 and POSIBA; NCT01276379) associated with Idylla liquid biopsy were presented at the European Society for Medical Oncology (ESMO) congress (19-23 Oct 2018 in Munich, Germany).
    • 19 Oct 2018 According to a Biocartis media release, results of an analysis of two prospective clinical trials (PULSE; NCT01288339 and POSIBA; NCT01276379) associated with Idylla liquid biopsy will be presented at the European Society for Medical Oncology (ESMO) congress (19-23 Oct 2018 in Munich, Germany).
    • 11 Oct 2016 Results of a subgroup analysis in the RAS/BRAF WT patients, presented at the 41st European Society for Medical Oncology Congress.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top